Refurbished Peptide Synthesizers Market: By Product (Reagent, Synthesizer, Chromatography), By Technology (Solid Phase, Liquid Phase, and Hybrid & Recombinant), By End User (Pharmaceuticals & Biotechnology, CRO and academic and research institutes) and Geography

Refurbished Peptide Synthesizers Market size was valued at USD 669.32 million in 2023 and is expected to reach USD 732 million by 2030, at a CAGR of 7.1% during the forecast period 2024-2030. Peptide-based medications are classified as small-molecule biologic or large-molecule biologics. Peptides, which fall in between small molecules and large proteins, have created a slew of regulatory issues. Chemically produced pharmaceuticals make up the majority of these medications. Despite the fact that the production method for several peptide medicines is similar, their action mechanisms differ significantly. As a result, creating an uniform set of regulatory rules that can effectively meet the safety and quality criteria for such a broad range of molecular entities with diverse modes of action is a difficult undertaking. There are no established guidelines for developing this class of medications from any regulatory agency.

The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are also at odds over the regulatory approval of peptide-based medications. According to the FDA, peptide medications are classified as small-molecule pharmaceuticals and fall under the jurisdiction of the FDA's Center for Drug Evaluation and Research (CDER); nevertheless, the EMA favors a centralized system over mutual recognition (the marketing of peptide-based drugs is allowed throughout the European Union under the centralized procedure). Due to the lack of a consistent set of rules, obtaining permits for therapeutic peptides has proven difficult, limiting their application areas. This is seen as a major stumbling block to the global peptide synthesis market's expansion.